所有图片(1)
About This Item
经验公式（希尔记法）:
C18H20FN3O4 · 0.5H2O
CAS号:
分子量:
370.38
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
levofloxacin
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O
InChI
1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1
InChI 密鑰
SUIQUYDRLGGZOL-RCWTXCDDSA-N
正在寻找类似产品? 访问 产品对比指南
應用
Levofloxacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Levofloxacin Tablets
- Levofloxacin Oral Solution
分析報告
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
其他說明
可能适用相应的销售限制。
相關產品
产品编号
说明
价格
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
R Davis et al.
Drugs, 47(4), 677-700 (1994-04-01)
Levofloxacin, an oral fluoroquinolone antibacterial agent, is the optical S-(-) isomer of ofloxacin. In vitro it is generally twice as potent as ofloxacin. Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate activity against anaerobes. Drug
Analysis and Standardization of Levofloxacin Substance.
Sedova, M. K., et al.
Pharmaceutical Chemistry Journal, 47.11, 620-626 (2014)
Kyung Eun Han et al.
American journal of ophthalmology, 157(6), 1144-1150 (2014-02-25)
To evaluate dry eye and meibomian gland dysfunction after cataract surgery. Prospective observational case series. We studied 58 eyes of 48 patients who underwent phacoemulsification and evaluated them preoperatively and at 1 month and 3 months postoperatively. Ocular symptom scores
Lixian He et al.
Anti-cancer drugs, 26(3), 359-362 (2014-12-09)
This pilot study assesses the safety and efficacy of once-daily, oral levofloxacin monotherapy in Chinese patients with low-risk febrile neutropenia. In this prospective, single-arm, open-label, multicenter clinical trial, 46 adult Chinese patients with solid tumors and low-risk febrile neutropenia were
Sabine Schuster et al.
Antimicrobial agents and chemotherapy, 58(11), 6870-6878 (2014-09-04)
Efflux is an important mechanism of bacterial multidrug resistance (MDR), and the inhibition of MDR pumps by efflux pump inhibitors (EPIs) could be a promising strategy to overcome MDR. 1-(1-Naphthylmethyl)-piperazine (NMP) and phenylalanine-arginine-β-naphthylamide (PAβN) are model EPIs with activity in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门